Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
Titel:
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
Auteur:
Barata, F. Queiroga, H. Teixeira, E. Almodovar, T. Soares, M. Parente, B. Mellidez, J.C. Alves, P. Antunes, A.